<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01989299</url>
  </required_header>
  <id_info>
    <org_study_id>VIP-HF Registry</org_study_id>
    <nct_id>NCT01989299</nct_id>
  </id_info>
  <brief_title>Ventricular Tachyarrhythmia Detection by Implantable Loop Recording in Patients With Heart Failure and Preserved Ejection Fraction</brief_title>
  <acronym>VIP-HF</acronym>
  <official_title>Ventricular Tachyarrhythmia Detection by Implantable Loop Recording in Patients With Heart Failure and Preserved Ejection Fraction (VIP-HF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure with preserved ejection fraction (HFPEF) is a large medical problem, for which
      no drug or device has a recommendation in current heart failure guidelines. Sudden cardiac
      death is suggested as the most common cause of death in HFPEF patients, although data is
      sparse. Use of an Implantable Loop Recorder (ILR) may be useful in patients with HFPEF to
      evaluate the incidence of sustained ventricular tachyarrhythmias. If ventricular
      tachyarrhythmias are seem frequently, treatment with an Implantable Cardioverter
      Defibrillator (ICD) may be an option in the future.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>The incidence of sustained ventricular tachyarrhythmias.</measure>
    <time_frame>2 years after ILR implantation</time_frame>
    <description>To study the incidence of ventricular tachyarrhythmias in patients with HFPEF at high-risk for arrhythmic mortality.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of atrial fibrillation (AF) in patients without baseline or history of AF</measure>
    <time_frame>2 years after ILR implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of progression of AF in patients without baseline or history of AF</measure>
    <time_frame>2 years after ILR implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of HF hospitalizations, all cause mortality, cardiovascular mortality, and sudden cardiac death</measure>
    <time_frame>2 years after ILR implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of non-sustained ventricular tachyarrhythmias</measure>
    <time_frame>2 years after ILR implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers (including ECG, Holter, echocardiography, CMR and blood biomarkers) for incident AF, and progression of AF in patients without baseline or history of AF</measure>
    <time_frame>2 years after ILR</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers (including ECG, Holter, echocardiography, CMR and blood biomarkers) of sustained ventricular tachyarrhythmias</measure>
    <time_frame>2 years after ILR implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers (including ECG, Holter, echocardiography, CMR and blood biomarkers) of non-sustained ventricular tachyarrhythmias</measure>
    <time_frame>2 years after ILR implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers (including echocardiography, ECG and other arrhythmogenic markers and blood biomarkers) for development of HF hospitalizations, sudden death, arrhythmic death, and all-cause mortality</measure>
    <time_frame>2 years after ILR implantation</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction (HFpEF)</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ILR implantation</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with heart failure with preserved ejection fraction (HFpEF)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Clinical criteria:

          1. Age &gt;18 years

          2. Written informed consent

          3. HF with moderate to severe symptoms NYHA II or III

          4. Hospitalization or emergency room visit for HF or symptom relief with diuretics within
             12 months

          5. Sinus rhythm or AF

        Echocardiographic criteria:

          1. LVEF &gt;40%

          2. Left atrial size (volume ≥34 mL/m2 or LA parasternal diameter ≥45), or left
             ventricular hypertrophy (septal thickness or posterior wall thickness ≥11 mm) or LV
             diastolic dysfunction (E/e' ≥13 or mean e' septal and lateral wall &lt;9 cm/s).

        Biomarker criteria:

          1. BNP &gt;100ng/L or NT-pro-BNP&gt;400ng/L if sinus rhythm

          2. BNP &gt;300ng/L or NT-pro-BNP&gt;1200ng/L if atrial fibrillation

        Exclusion Criteria:

          1. Patients unwilling or unable to sign informed consent

          2. Patients with a pacemaker or ICD

          3. Indication for ICD therapy according to the ESC guidelines

          4. Life expectancy of less than one year

          5. Significant coronary artery disease or myocardial infarction &lt; 3 months

          6. Complex congenital heart disease

          7. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michiel Rienstra, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabelle C van Gelder, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander H Maass, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dirk J Veldhuisen, van, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth-TweeSteden Ziekenhuis (ETZ)</name>
      <address>
        <city>Tilburg</city>
        <zip>5022 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2013</study_first_submitted>
  <study_first_submitted_qc>November 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2013</study_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>M. Rienstra</investigator_full_name>
    <investigator_title>dr.</investigator_title>
  </responsible_party>
  <keyword>Heart failure with preserved ejection fraction (HFpEF)</keyword>
  <keyword>ILR</keyword>
  <keyword>ventricular tachyarrhythmias</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

